FDA targets Lilly, Novartis, BMS and more in deluge of marketing letters - Fierce Pharma

After the FDA announced it was cracking down on what it has determined | After the FDA announced it was cracking down on what it has determined to be “misleading” or “deceptive” direct-to-consumer pharmaceutical ads, the floodgates have opened.